RecruitingPhase 2NCT06440993

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Studying Carcinoma of gallbladder and extrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Principal Investigator
Salah-Eddin SE Al-Batran, Prof. Dr.
Frankfurter Institut fuer Klinische Krebsforschung IKF GmbH
Intervention
Gemcitabine(drug)
Enrollment
42 enrolled
Eligibility
18 years · All sexes
Timeline
20242028

Study locations (10)

Collaborators

Universitätsklinikum Düsseldorf, Germany · Universitätsklinikum Köln · AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06440993 on ClinicalTrials.gov

Other trials for Carcinoma of gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Carcinoma of gallbladder and extrahepatic biliary tract

← Back to all trials